Will Medicare Cover Zepbound in 2026? A Detailed Guide

As new, effective medications for weight management become available, many people are asking important questions about access and affordability. If you’re a Medicare beneficiary curious about Zepbound, you’ve come to the right place for clear information on what to expect for coverage in 2026 and beyond.

Understanding Zepbound and Its Purpose

Before diving into the specifics of Medicare, it’s helpful to understand what Zepbound is. Zepbound is the brand name for the medication tirzepatide, which is manufactured by Eli Lilly. In late 2023, the U.S. Food and Drug Administration (FDA) approved Zepbound specifically for chronic weight management. It is intended for adults with obesity or those who are overweight and have at least one weight-related health condition, such as high blood pressure or type 2 diabetes.

Zepbound works by activating two different hormone receptors in the body, which helps regulate appetite and food intake, leading to significant weight loss for many users. Its effectiveness has made it a popular topic, especially among those looking for medical assistance in their weight management journey.

The Current Barrier: Why Medicare Doesn't Cover Weight-Loss Drugs

To understand the future of Zepbound coverage, we must first look at the current rules. The primary reason Medicare does not currently cover Zepbound when prescribed solely for weight loss is due to a specific law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which established the Part D prescription drug program, explicitly excludes certain categories of drugs from coverage. Among these are drugs prescribed for anorexia, weight loss, or weight gain. This means that under current law, Medicare Part D plans are prohibited from covering medications like Zepbound or Wegovy if the prescription is written only for the purpose of losing weight.

This has been a source of frustration for many beneficiaries and doctors who see obesity as a serious medical condition linked to numerous other health problems that Medicare does cover, such as heart disease and diabetes.

The Path to Potential Coverage in 2026

The conversation around coverage began to change significantly in 2024, opening a potential pathway for Zepbound to be covered by 2026. This change does not come from a new law, but from new guidance issued by the Centers for Medicare & Medicaid Services (CMS).

The New CMS Guidance Explained

In early 2024, CMS clarified its position. The guidance stated that if a weight-loss drug also receives FDA approval to treat another “medically accepted indication,” then Medicare Part D plans can choose to cover it for that specific health benefit.

A perfect example of this is heart health. If a drug like Zepbound is proven to reduce the risk of heart attacks, strokes, or other cardiovascular events in people with obesity, that would be considered a medically accepted indication beyond simple weight loss. Under this new guidance, Medicare Part D plans would then have the option to add the drug to their formularies for that specific use.

Zepbound’s Clinical Trials are Key

This is where the 2026 timeline becomes relevant. Eli Lilly, the maker of Zepbound, is currently conducting large-scale clinical trials to demonstrate that tirzepatide provides significant cardiovascular benefits. These studies are designed to produce the exact kind of data the FDA would need to expand Zepbound’s approved uses.

If these trials are successful and the FDA grants this expanded approval, it would unlock the door for Medicare Part D coverage. The process involves several steps:

  1. Completion of the clinical trials.
  2. Analysis of the data by Eli Lilly.
  3. Submission of the data to the FDA to request expanded approval.
  4. Review and final decision by the FDA.

This entire process takes time, which is why experts and analysts often point to 2026 as a realistic target for when these changes could take effect and plans might begin offering coverage.

What Would "Coverage" Actually Mean for You?

It is critical to understand that “coverage” does not mean the medication would be free. If Zepbound is covered by some Medicare Part D or Medicare Advantage plans in the future, it would be treated like any other prescription drug on the plan’s formulary.

Here is what you could expect:

  • Plan Formularies: Not all plans would be required to cover it. Each private insurance company that offers a Part D or Medicare Advantage plan would decide whether to include Zepbound on its list of covered drugs (its formulary).
  • Tier Placement: Plans would place Zepbound on a specific drug tier, which determines your out-of-pocket cost. As a new, expensive brand-name drug, it would likely be placed on a higher, more costly tier.
  • Costs: You would still be responsible for your plan’s annual deductible, as well as a copayment or coinsurance for each prescription fill.
  • Prior Authorization: It is almost certain that plans would require prior authorization. This means your doctor would need to submit documentation to the insurance company proving that the medication is medically necessary for you based on the plan’s specific criteria.

What You Can Do While You Wait

While the potential for coverage in 2026 is promising, it is not guaranteed. In the meantime, there are steps you can take.

  1. Talk to Your Doctor: This is the most important step. Discuss your weight management goals and overall health. Your doctor can determine if Zepbound is appropriate for you and can discuss all available treatment options.
  2. Check for Other Conditions: The same active ingredient in Zepbound (tirzepatide) is also sold under the brand name Mounjaro for the treatment of type 2 diabetes. If you have type 2 diabetes, Medicare Part D already covers Mounjaro.
  3. Look into Legislative Changes: Advocacy groups are actively supporting the Treat and Reduce Obesity Act (TROA). If passed, this federal law would change the original 2003 rule and allow Medicare to cover FDA-approved weight-loss medications. You can follow the progress of this bill to stay informed.

Frequently Asked Questions

What is the difference between Zepbound and Mounjaro? They are the exact same medication, tirzepatide. The only difference is the brand name and the FDA-approved indication. Mounjaro is approved to treat type 2 diabetes, while Zepbound is approved for chronic weight management.

Does Medicare Part B cover any weight-loss treatments? Yes, but in a limited capacity. Medicare Part B may cover intensive behavioral therapy for obesity. This involves counseling sessions with a primary care provider to help you with diet and exercise. It does not cover medications.

If Zepbound is covered in 2026, will it be affordable? Affordability will depend entirely on your specific Medicare Part D or Medicare Advantage plan. Costs will vary based on the plan’s deductible, formulary tier, and copayments. You will need to compare plans carefully during the annual Open Enrollment period to find one that offers the best coverage for your needs.